Loading...

Exelixis

Nasdaq:EXEL
Snowflake Description

Outstanding track record with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EXEL
Nasdaq
$6B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
EXEL Share Price and Events
7 Day Returns
4%
NasdaqGS:EXEL
-0.4%
US Biotechs
0.3%
US Market
1 Year Returns
6.1%
NasdaqGS:EXEL
-9%
US Biotechs
0.7%
US Market
EXEL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Exelixis (EXEL) 4% 6.9% -15% 6.1% 169.7% 461.4%
US Biotechs -0.4% -1% -8.9% -9% 11.4% 5.1%
US Market 0.3% 0.4% 0.6% 0.7% 37.2% 37.4%
1 Year Return vs Industry and Market
  • EXEL outperformed the Biotechs industry which returned -9% over the past year.
  • EXEL outperformed the Market in United States of America which returned 0.7% over the past year.
Price Volatility
EXEL
Industry
5yr Volatility vs Market

Value

 Is Exelixis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Exelixis to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Exelixis.

NasdaqGS:EXEL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 14 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:EXEL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.318 (1 + (1- 21%) (0.32%))
1.215
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.215 * 5.96%)
9.97%

Discounted Cash Flow Calculation for NasdaqGS:EXEL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Exelixis is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:EXEL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.97%)
2019 278.43 Analyst x2 253.18
2020 546.10 Analyst x2 451.54
2021 218.50 Analyst x1 164.28
2022 374.79 Analyst x1 256.24
2023 516.86 Analyst x1 321.31
2024 527.09 Est @ 1.98% 297.96
2025 538.70 Est @ 2.2% 276.91
2026 551.43 Est @ 2.36% 257.74
2027 565.06 Est @ 2.47% 240.16
2028 579.47 Est @ 2.55% 223.95
Present value of next 10 years cash flows $2,743.26
NasdaqGS:EXEL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $579.47 × (1 + 2.73%) ÷ (9.97% – 2.73%)
$8,218.20
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,218.20 ÷ (1 + 9.97%)10
$3,176.10
NasdaqGS:EXEL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,743.26 + $3,176.10
$5,919.36
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,919.36 / 301.77
$19.62
NasdaqGS:EXEL Discount to Share Price
Calculation Result
Value per share (USD) From above. $19.62
Current discount Discount to share price of $20.66
= -1 x ($20.66 - $19.62) / $19.62
-5.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Exelixis is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Exelixis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Exelixis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:EXEL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $2.17
NasdaqGS:EXEL Share Price ** NasdaqGS (2019-06-17) in USD $20.66
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,093 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Exelixis.

NasdaqGS:EXEL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:EXEL Share Price ÷ EPS (both in USD)

= 20.66 ÷ 2.17

9.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Exelixis is good value based on earnings compared to the US Biotechs industry average.
  • Exelixis is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Exelixis's expected growth come at a high price?
Raw Data
NasdaqGS:EXEL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 9.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts
16.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.08x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

NasdaqGS:EXEL PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 9.5x ÷ 16.9%

0.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Exelixis is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Exelixis's assets?
Raw Data
NasdaqGS:EXEL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.59
NasdaqGS:EXEL Share Price * NasdaqGS (2019-06-17) in USD $20.66
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 2.9x
United States of America Market PB Ratio Median Figure of 5,245 Publicly-Listed Companies 1.79x
NasdaqGS:EXEL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:EXEL Share Price ÷ Book Value per Share (both in USD)

= 20.66 ÷ 4.59

4.5x

* Primary Listing of Exelixis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Exelixis is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Exelixis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Exelixis has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Exelixis expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Exelixis expected to grow at an attractive rate?
  • Exelixis's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Exelixis's earnings growth is expected to exceed the United States of America market average.
  • Exelixis's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:EXEL Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:EXEL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts 16.9%
NasdaqGS:EXEL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts 15.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:EXEL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:EXEL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,660 871 703 6
2022-12-31 1,508 789 582 8
2021-12-31 1,275 653 466 11
2020-12-31 1,111 526 387 14
2019-12-31 919 390 302 14
NasdaqGS:EXEL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 856 506 650
2018-12-31 854 416 690
2018-09-30 745 364 368
2018-06-30 672 238 323
2018-03-31 585 169 253
2017-12-31 452 166 154
2017-09-30 410 197 150
2017-06-30 320 154 58
2017-03-31 257 122 6
2016-12-31 191 210 -70
2016-09-30 124 90 -147
2016-06-30 71 61 -181

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Exelixis's earnings are expected to grow by 16.9% yearly, however this is not considered high growth (20% yearly).
  • Exelixis's revenue is expected to grow by 15.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:EXEL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below

All data from Exelixis Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:EXEL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.14 2.46 1.45 6.00
2022-12-31 1.78 2.23 1.25 8.00
2021-12-31 1.45 1.87 0.77 10.00
2020-12-31 1.22 1.59 0.63 13.00
2019-12-31 0.97 1.17 0.77 13.00
NasdaqGS:EXEL Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 2.17
2018-12-31 2.32
2018-09-30 1.24
2018-06-30 1.09
2018-03-31 0.86
2017-12-31 0.52
2017-09-30 0.52
2017-06-30 0.21
2017-03-31 0.02
2016-12-31 -0.28
2016-09-30 -0.62
2016-06-30 -0.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Exelixis is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Exelixis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Exelixis has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Exelixis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Exelixis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Exelixis has delivered over 20% year on year earnings growth in the past 5 years.
  • Exelixis's 1-year earnings growth exceeds its 5-year average (156.8% vs 73.6%)
  • Exelixis's earnings growth has exceeded the US Biotechs industry average in the past year (156.8% vs 52.3%).
Earnings and Revenue History
Exelixis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Exelixis Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:EXEL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 855.59 649.99 212.49 207.79
2018-12-31 853.83 690.07 206.37 182.26
2018-09-30 745.30 368.47 200.27 157.19
2018-06-30 672.41 322.97 190.28 140.99
2018-03-31 585.31 253.07 179.09 126.72
2017-12-31 452.48 153.86 159.36 112.17
2017-09-30 409.99 150.49 126.09 103.77
2017-06-30 319.67 58.08 120.42 95.48
2017-03-31 256.91 5.64 115.58 90.25
2016-12-31 191.45 -70.22 116.15 95.97
2016-09-30 123.81 -146.91 120.29 95.64
2016-06-30 71.47 -181.17 105.67 101.47
2016-03-31 43.21 -185.80 82.63 103.00
2015-12-31 37.17 -161.74 57.31 96.35
2015-09-30 34.59 -178.13 49.93 112.53
2015-06-30 31.02 -195.15 41.99 130.07
2015-03-31 29.59 -229.09 45.67 156.54
2014-12-31 25.11 -261.30 50.83 189.10
2014-09-30 22.11 -281.34 54.70 199.05
2014-06-30 21.28 -285.90 58.39 202.77
2014-03-31 26.57 -274.65 55.10 200.88
2013-12-31 31.34 -244.76 50.96 178.76
2013-09-30 34.81 -226.21 47.15 161.66
2013-06-30 42.65 -191.90 40.90 144.98
2013-03-31 38.61 -166.22 34.48 128.52
2012-12-31 47.45 -147.65 31.84 128.88
2012-09-30 132.94 -49.16 29.02 127.16
2012-06-30 247.90 61.52 29.85 133.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Exelixis made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Exelixis used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.
  • Exelixis has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Exelixis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Exelixis has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Exelixis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Exelixis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Exelixis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Exelixis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Exelixis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -345.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Exelixis Company Filings, last reported 2 months ago.

NasdaqGS:EXEL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,385.02 19.96 799.65
2018-12-31 1,287.45 14.97 693.33
2018-09-30 915.97 14.98 634.62
2018-06-30 774.97 21.35 499.92
2018-03-31 669.77 0.00 426.92
2017-12-31 284.96 15.48 387.77
2017-09-30 238.72 0.00 367.10
2017-06-30 148.51 0.00 349.26
2017-03-31 119.75 113.35 424.27
2016-12-31 89.32 189.12 419.80
2016-09-30 32.02 190.86 319.68
2016-06-30 -186.13 396.06 328.12
2016-03-31 -155.95 388.66 322.12
2015-12-31 -140.81 417.94 167.06
2015-09-30 -74.23 377.89 197.81
2015-06-30 -188.19 371.23 76.60
2015-03-31 -146.76 368.43 107.25
2014-12-31 -114.83 356.97 144.29
2014-09-30 -58.51 355.22 192.00
2014-06-30 3.24 348.97 233.52
2014-03-31 71.48 343.02 273.57
2013-12-31 66.24 347.24 242.45
2013-09-30 132.76 341.59 279.22
2013-06-30 196.33 336.14 351.97
2013-03-31 254.85 330.85 356.56
2012-12-31 296.43 335.74 411.44
2012-09-30 340.85 335.29 472.35
2012-06-30 99.05 182.70 207.04
  • Exelixis's level of debt (-0.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (485% vs -0.2% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Exelixis has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Exelixis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Exelixis has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Exelixis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Exelixis dividends. Estimated to be 0% next year.
If you bought $2,000 of Exelixis shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Exelixis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Exelixis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:EXEL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:EXEL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Exelixis has not reported any payouts.
  • Unable to verify if Exelixis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Exelixis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Exelixis has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Exelixis's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Exelixis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Exelixis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Exelixis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Exelixis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Morrissey
COMPENSATION $7,977,535
AGE 57
TENURE AS CEO 8.9 years
CEO Bio

Dr. Michael M. Morrissey, Ph.D., has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as the President of Research and Development at Exelixis Inc. since January 4, 2007 until July 2010. Dr. Morrissey served as an Executive Vice President of Discovery of Exelixis Inc., from January 2006 to December 2006 and its Senior Vice President of Discovery Research from January 2003 to December 2005. Dr. Morrissey served as Vice President of Discovery Research of Exelixis Inc. from February 2000 to December 2002. Dr. Morrissey served as Vice President of Discovery Research, where he was responsible for all aspects of drug discovery from 1991 to 2000 and Director of Pharmaceutical Discovery and Unit Head of Medicinal Chemistry of Berlex Biosciences, a pharmaceutical company. Dr. Morrissey led the effort to expand and modernize the drug discovery capabilities at Berlex through the application of high-throughput screening, combinatorial and medicinal chemistry and structural biology. Dr. Morrissey served as a Senior Scientist and Project Team Leader in Medicinal Chemistry of CIBA-Geigy Corporation, a pharmaceutical company from 1986 to 1991. Over the past nineteen years, Dr. Morrissey has led discovery efforts that identified 13 clinical candidates, including four that have advanced to Phase 2 clinical trials for a variety of cardiovascular and inflammatory indications. He has been a Director at Exelixis, Inc. since July 2010. Dr. Morrissey serves as Member of the Scientific Advisory Board of Resolvyx Pharmaceuticals, Inc. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 68 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds Ph.D. in Chemistry from Harvard University and his B.S. Honors in Chemistry from the University of Wisconsin.

CEO Compensation
  • Michael's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Michael's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Exelixis management team in years:

3.9
Average Tenure
57
Average Age
  • The tenure for the Exelixis management team is about average.
Management Team

Stelios Papadopoulos

TITLE
Co-Founder & Chairman
COMPENSATION
$421K
AGE
70

Michael Morrissey

TITLE
CEO, President & Director
COMPENSATION
$8M
AGE
57
TENURE
8.9 yrs

Chris Senner

TITLE
Executive VP & CFO
COMPENSATION
$3M
AGE
50
TENURE
3.9 yrs

Peter Lamb

TITLE
Executive VP of Scientific Strategy & Chief Scientific Officer
COMPENSATION
$3M
AGE
57
TENURE
12.4 yrs

Jeffrey Hessekiel

TITLE
Executive VP
COMPENSATION
$3M
AGE
49
TENURE
5.3 yrs

Gisela Schwab

TITLE
President of Product Development & Medical Affairs and Chief Medical Officer
COMPENSATION
$4M
AGE
61
TENURE
13.3 yrs

Dana Aftab

TITLE
Executive Vice President of Business Operations
TENURE
3.3 yrs

Susan Hubbard

TITLE
Executive Vice President of Public Affairs & Investor Relations
TENURE
2.5 yrs

Jon Berndt

TITLE
Vice President of Sales
TENURE
3.8 yrs

Gregg Bernier

TITLE
Vice President of Marketing
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the Exelixis board of directors in years:

16.7
Average Tenure
64.5
Average Age
  • The average tenure for the Exelixis board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Michael Morrissey

TITLE
CEO, President & Director
COMPENSATION
$8M
AGE
57
TENURE
8.9 yrs

Charlie Cohen

TITLE
Independent Director
COMPENSATION
$409K
AGE
67
TENURE
23.6 yrs

Stelios Papadopoulos

TITLE
Co-Founder & Chairman
COMPENSATION
$421K
AGE
70
TENURE
21.4 yrs

Jack Wyszomierski

TITLE
Independent Director
COMPENSATION
$406K
AGE
62
TENURE
15.3 yrs

George Poste

TITLE
Independent Director
COMPENSATION
$396K
AGE
74
TENURE
14.8 yrs

Alan Garber

TITLE
Independent Director
COMPENSATION
$391K
AGE
62
TENURE
14.4 yrs

Lance Willsey

TITLE
Independent Director
COMPENSATION
$385K
AGE
56
TENURE
22.2 yrs

George Scangos

TITLE
Independent Director
COMPENSATION
$376K
AGE
70
TENURE
22.7 yrs

Vincent Marchesi

TITLE
Independent Director
COMPENSATION
$391K
AGE
82
TENURE
18.1 yrs

José Baselga

TITLE
Member of Scientific Advisory Board
AGE
58
TENURE
12.4 yrs
Who owns this company?
Recent Insider Trading
  • Exelixis insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
11. May 19 Sell Lance Willsey Individual 08. May 19 08. May 19 -50,000 $20.36 $-1,018,000
04. May 19 Sell Christopher Senner Individual 03. May 19 03. May 19 -36,261 $20.70 $-750,603
28. Feb 19 Sell Patrick Haley Individual 25. Feb 19 25. Feb 19 -4,272 $22.27 $-95,137
20. Feb 19 Sell Charles Cohen Individual 14. Feb 19 19. Feb 19 -248,180 $22.41 $-5,494,906
01. Dec 18 Sell Jeffrey Hessekiel Individual 28. Nov 18 30. Nov 18 -14,818 $19.91 $-285,290
01. Dec 18 Sell Christopher Senner Individual 30. Nov 18 30. Nov 18 -8,791 $19.70 $-173,183
10. Nov 18 Sell Patrick Haley Individual 07. Nov 18 07. Nov 18 -20,000 $17.32 $-346,400
26. Sep 18 Sell George Scangos Individual 24. Sep 18 24. Sep 18 -25,000 $16.85 $-421,250
08. Aug 18 Sell Patrick Haley Individual 06. Aug 18 06. Aug 18 -2,361 $20.92 $-49,392
X
Management checks
We assess Exelixis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Exelixis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Shareholders Own Exelixis, Inc. (NASDAQ:EXEL)?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … NasdaqGS:EXEL Income Statement, June 10th 2019 Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. … Insider Ownership Of Exelixis The definition of an insider can differ slightly between different countries, but members of the board of directors always count.

Simply Wall St -

Exelixis, Inc. (NASDAQ:EXEL) Delivered A Better ROE Than Its Industry

The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Exelixis: 47% = US$650m ÷ US$1.4b (Based on the trailing twelve months to March 2019.) Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. … The Importance Of Debt To Return On Equity Companies usually need to invest money to grow their profits. … In my book the highest quality companies have high return on equity, despite low debt.

Simply Wall St -

Here's What Exelixis, Inc.'s (NASDAQ:EXEL) P/E Ratio Is Telling Us

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Looking at earnings over the last twelve months, Exelixis has a P/E ratio of 9.56. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in Exelixis (NASDAQ:EXEL). … Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. … Exelixis shareholders can take confidence from the fact that EBIT margins are up from 37% to 52%, and revenue is growing.

Simply Wall St -

Need To Know: Exelixis, Inc. (NASDAQ:EXEL) Insiders Have Been Selling Shares

In the last twelve months, the biggest single sale by an insider was when the Independent Director, Charles Cohen, sold US$5.5m worth of shares at a price of US$22.41 per share. … That means that even when the share price was below the current price of US$23.57, an insider wanted to cash in some shares. … As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation.

Simply Wall St -

Is Exelixis, Inc.'s (NASDAQ:EXEL) Liquidity Good Enough?

Today we will look at EXEL’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Note that this commentary is very high-level and solely focused on financial health, so I suggest you dig deeper yourself. … Does EXEL Produce Much Cash Relative To Its Debt?

Simply Wall St -

How Should Investors Feel About Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Michael Morrissey's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$7.1b, and pays its CEO total annual compensation worth US$9.4m.

Simply Wall St -

Did The Underlying Business Drive Exelixis's Lovely 491% Share Price Gain?

It's also good to see the share price up 14% over the last quarter. … In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. … One flawed but reasonable way to assess how sentiment around a company has changed, is to compare the earnings per share (EPS) with the share price.

Simply Wall St -

Why Exelixis, Inc. (NASDAQ:EXEL) Looks Like A Quality Company

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … That means that for every $1 worth of shareholders' equity, it generated $0.40 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Here's What Exelixis, Inc.'s (NASDAQ:EXEL) P/E Ratio Is Telling Us

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … Exelixis has a price to earnings ratio of 18.77, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

Company Info

Description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Details
Name: Exelixis, Inc.
EXEL
Exchange: NasdaqGS
Founded: 1994
$6,234,513,574
301,767,356
Website: http://www.exelixis.com
Address: Exelixis, Inc.
1851 Harbor Bay Parkway,
Alameda,
California, 94502,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS EXEL Common Stock Nasdaq Global Select US USD 11. Apr 2000
DB EX9 Common Stock Deutsche Boerse AG DE EUR 11. Apr 2000
LSE 0IJO Common Stock London Stock Exchange GB USD 11. Apr 2000
Number of employees
Current staff
Staff numbers
484
Exelixis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/17 23:38
End of day share price update: 2019/06/17 00:00
Last estimates confirmation: 2019/06/05
Last earnings filing: 2019/05/01
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.